Embolic stroke of undetermined source (ESUS) accounts for up of 25% of all ischaemic strokes and its risk of recurrence has been estimated to be approximately 5% per year [1,2]. The concept of ESUS was proposed in 2014 to classify a subset of ischaemic stroke with no identifiable causes of embolism despite a structured diagnostic work-up [3]. As the most accepted concept of the ESUS retains that most cryptogenic strokes may be thromboembolic, these would likely benefit from anticoagulant therapy.
